<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01749072</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-S464</org_study_id>
    <nct_id>NCT01749072</nct_id>
  </id_info>
  <brief_title>Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients</brief_title>
  <official_title>A Phase Ⅱ Randomized Clinical Trial Comparing Vinorelbine-ifosfamide With Gefitinib as Third-line Treatment in Advanced EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the National Comprehensive Cancer Network (NCCN) guideline for NSCLC, epidermal growth
      factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is recommended as the third-line
      treatment for EGFR gene mutation negative NSCLC patients who failed to the first-line
      platinum doublet chemotherapy [i.e. paclitaxel-carboplatin (PC) or gemcitabine-cisplatin
      (GP)] and the second-line chemotherapy with docetaxel or pemetrexed. But as we know, if
      patients had no EGFR gene mutation, EGFR-TKI treatment is not effective. The overall survival
      is short and the objective response rate is low. As for EGFR gene wild type patients with
      good performance status, besides EGFR-TKI treatment, other first generation cytotoxic drugs
      i.e. vinorelbine or ifosfamide maybe an alternative treatment. So the purpose of this
      clinical trial is to compare the effectiveness and safety of vinorelbine-ifosfamide with
      gefitinib in advanced or metastatic EGFR gene mutation negative NSCLC patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ifosfamide is a first generation cytotoxic drug to treat NSCLC. Phase Ⅱ studies demonstrated
      that single-agent ifosfamide administrated by various schedules produces response rates of
      15-29%, with media survival times of 5-7 months. Ifosfamide has also been used in various
      combination regimens to treat NSCLC, including platinum based and non-platinum regimens. But
      in refractory NSCLC patients platinum and some third generation cytotoxic drugs have been
      used before. So in this study, ifosfamide is combined with vinorelbine. In previous study,
      Masters reported the objective response rate was 40% and the median survival duration was 50
      weeks, with a 1-year survival rate of 48% with vinorelbine-ifosfamide regimen [Vinorelbine 15
      mg/m2 on days 1-3, and ifosfamide 2.0g/m2 on days 1-3 with granulocyte-colony stimulating
      factor (G-CSF) support]. The dose limiting toxicity (DLT) of this regimen is
      myelosuppression. In our experience, the regimen of vinorelbine 25mg/m2 d1, d8 and ifosfamide
      1.25g/m2 d1-d3 with Mesna uroprotection is safe in Chinese population and the objective
      response rate is about 7% (data not published).

      Gefitinib is the first small molecule inhibitor that has directed activity towards EGFR and
      has shown appreciable response rates in phase Ⅱ trials of patients with previously treated
      advanced NSCLC. In the posterior analysis of Iressa Dose Evaluation in Advanced Lung Cancer
      (IDEAL) and IRESSA Survival Evaluation in Lung Cancer (ISEL) trials, the response rate with
      gefitinib ranges from 2.6% to 10% in wild-type EGFR gene NSCLC patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 52 weeks (about one year)</time_frame>
    <description>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 100 weeks</time_frame>
    <description>From date of randomization until the date of death from any cause, assessed up to 100 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>up to 9 weeks</time_frame>
    <description>The objective response rate includes the complete remission and partial remission rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the score of functional assessment of cancer treatment-lung (FACT-L)</measure>
    <time_frame>Up to 100 weeks</time_frame>
    <description>FACL-L is assessed at different time points.(Date of randomization, 1 week after chemotherapy/EGFR-TKI, every cycle of chemotherapy/EGFR-TKI, every month of EGFR-TKI treatment/observation, up to 100 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to six months</time_frame>
    <description>The adverse events are assessed by National Cancer Institute-Common Toxicity Criteria (Version 3.0) (NCI-CTC).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Effects of Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Gefitinib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Gefitinib group Gefitinib (Iressa) 250mg once per day until progression disease or intolerant side effects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vinorelbine-Ifosfamide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>VI group Vinorelbine 25mg/m2 d1,d8;Ifosfamide 1.25g/m2 d1-d3(Usually Ifosfamide 2g d1-d3 with Mesna 400mg 0,4,8hours after Ifosfamide administration for 3 days);every 3 weeks;at least for 2-6 cycles depending on the progression disease or the patient's physical condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib group</intervention_name>
    <description>Gefitinib 250mg once per day until the progression disease or intolerant side effects</description>
    <arm_group_label>Gefitinib</arm_group_label>
    <other_name>Gefitinib (Iressa)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine, Ifosfamide, Mesna</intervention_name>
    <description>Vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m1 d1-d3 (Usually 2g d1-d3); Mesna 400mg 0,4,8 hours after Ifosfamide administration for uroprotection d1-d3;</description>
    <arm_group_label>Vinorelbine-Ifosfamide</arm_group_label>
    <other_name>VI group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age range:18-70 years old

          -  life expectancy more than 12 weeks

          -  histologically or cytologically confirmed inoperable NSCLC (stage ⅢB/Ⅳ)

          -  ineligible for curative radiotherapy

          -  no prior radiotherapy for the target lesions

          -  Eastern Cooperative Oncology Group (ECOG) performance score of 0-2;

          -  prior treatments include first-line platinum doublet chemotherapy i.e. PC or GP and
             second-line chemotherapy with docetaxel or pemetrexed;

          -  No EGFR gene mutation detected by Scorpions-ARMS;

          -  at least one bidimensionally measurable or radiographically assessable lesion;

          -  adequate bone marrow reserve;

          -  adequate hepatic and renal function;

        Exclusion Criteria:

          -  prior treatments including any of the following drugs:gefitinib,vinorelbine and
             ifosfamide;

          -  additional malignancies;

          -  uncontrolled systemic disease;

          -  any evidence of clinically active interstitial lung disease;

          -  newly diagnosed central nervous system (CNS) metastasis and not treated by
             radiotherapy or surgery;

          -  pregnancy or breast feeding phase;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mengzhao Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Respiratory Medicine, Peking Unoin Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mengzhao Wang, MD</last_name>
    <phone>010-69155039</phone>
    <phone_ext>+86</phone_ext>
    <email>mengzhaowang@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Zhao, MD</last_name>
    <phone>010-69158206</phone>
    <phone_ext>+86</phone_ext>
    <email>pumchzj@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Respiratory Medicine, Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mengzhao Wang, MD</last_name>
      <phone>010-69155039</phone>
      <phone_ext>+86</phone_ext>
      <email>mengzhaowang@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Jing Zhao, MD</last_name>
      <phone>010-69158206</phone>
      <phone_ext>+86</phone_ext>
      <email>pumchzj@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wei Zhong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinmei Luo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Thatcher N, Anderson H, Smith DB, Steward WP, Webb K, Hilton A, Rahman A. Ifosfamide by bolus as treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 1986;18 Suppl 2:S30-3.</citation>
    <PMID>3028661</PMID>
  </results_reference>
  <results_reference>
    <citation>Holoye PY, Glisson BS, Lee JS, Dhingra HM, Murphy WK, Umsawasdi T, Levy JK, Jeffries D, Raber MN, Hong WK. Ifosfamide with mesna uroprotection in the management of lung cancer. Am J Clin Oncol. 1990 Apr;13(2):148-55.</citation>
    <PMID>2156418</PMID>
  </results_reference>
  <results_reference>
    <citation>Masters GA, Hoffman PC, Hsieh A, Drinkard LC, Mick R, Samuels BL, Guaspari A, Golomb HM, Vokes EE. Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer. J Clin Oncol. 1997 Mar;15(3):884-92.</citation>
    <PMID>9060524</PMID>
  </results_reference>
  <results_reference>
    <citation>Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005 Nov 1;23(31):8081-92. Epub 2005 Oct 3.</citation>
    <PMID>16204011</PMID>
  </results_reference>
  <results_reference>
    <citation>Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006 Nov 1;24(31):5034-42.</citation>
    <PMID>17075123</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2012</study_first_submitted>
  <study_first_submitted_qc>December 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2012</study_first_posted>
  <last_update_submitted>December 12, 2012</last_update_submitted>
  <last_update_submitted_qc>December 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non small cell lung cancer</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>gefitinib</keyword>
  <keyword>vinorelbine</keyword>
  <keyword>ifosfamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Mesna</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

